

**ASX Announcement**

**04 February 2025**

**120 German Hospitals legally entitled to negotiate fee for OncoSil™**

**Sydney, Australia – 04 February 2025:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce that German Institute for the Hospital Remuneration System (InEK) has authorised 120 German hospitals to negotiate funding for the OncoSil™ device classification under the innovation funding (NUB) program with the statutory health insurance (SHI) companies during the annual budget negotiations. This represents a significant increase of 43% compared to 2024 (84 hospitals), underscoring the demand in Germany and growing recognition of the OncoSil™ device within the German healthcare system.

OncoSil had been granted a “Positive Status 1” classification under the innovation funding (NUB) program in 2021. In October 2024; the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) approved the Directive for testing the new treatment method: "Endoscopic injection-implantation of 32P-labeled microparticles in unresectable, locally advanced pancreatic tumors." Following that in January 2025, the Ministry of Health approval has been received and the Coverage with Evidence Development Study Directive has been published in the National German Gazette.

**Nigel Lange, CEO & Managing Director of OncoSil Medical, said:**

*" We are delighted by the continued progress in Germany with the expanded authorisation for hospitals to negotiate funding for the OncoSil™ device under the NUB innovation program. This important milestone reflects growing acceptance of the OncoSil device by the German healthcare professionals on the clinical potential of our treatment and reinforces our commitment to delivering life-changing solutions for patients with locally advanced pancreatic cancer. The approval from the German Ministry of Health and the publication of the Coverage with Evidence Development Study Directive further solidifies our position in this important market. We remain dedicated to advancing innovative treatments that improve patient outcomes worldwide."*

**For further information, please contact:**

<p><b>Mr. Nigel Lange</b>          CEO &amp; Managing Director          E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a>          T: +49 30 300 149 3043</p>	<p><b>Mr. Christian Dal Cin</b>          CFO &amp; Company Secretary          E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a>          T: +61 3 9824 5254</p>	<p><b>Ms. Julia Maguire</b>  <b>The Capital Network</b>          Media and Investor Enquiries          E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a>          T: +61 2 8999 3699</p>
---	---	--

For personal use only

### **About OncoSil Medical**

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

**References:** 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>